Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
about
The Promise and the Hype of 'Personalised Medicine'.Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.Haplotype-based stratification of Huntington's disease.Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.Modern Genome Editing Technologies in Huntington's Disease Research.Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process.Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1.Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regressionRNA biology of disease-associated microsatellite repeat expansions.2016 William Allan Award: Human Disease Research: Genetic Cycling and Re-cycling.CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's DiseaseGene suppression approaches to neurodegeneration.CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.Therapies targeting DNA and RNA in Huntington's disease.Design of a "Mini" Nucleic Acid Probe for Cooperative Binding of an RNA-Repeated Transcript Associated with Myotonic Dystrophy Type 1.The prospects of CRISPR-based genome engineering in the treatment of neurodegenerative disorders.Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's Disease.Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells.Population-specific genetic modification of Huntington's disease in Venezuela.CRISPR/Cas9: the Jedi against the dark empire of diseases.CRISPR therapeutic tools for complex genetic disorders and cancer (Review).Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation.
P2860
Q33738293-0CE7CAC8-A96C-4712-B173-87F64FEE63BDQ33752590-C6970FAB-162B-4534-BC75-FE6456BFADDCQ38612630-E65D3815-8C73-4902-8D8D-652635EE494CQ38772195-AD8E47FB-43E6-4A9A-B5B3-4429E1A2EFB7Q39106522-E6428E91-E681-45FE-8D5B-5B08D9C74F0CQ39112084-B454A932-FD55-40BB-8C84-DFC7726EDDC4Q41235149-2F656A6D-64C4-4811-B460-5976EBF18368Q41511092-9EBC9F98-D5BE-4B68-BDC7-12FFEFE63BC0Q41542861-579BF4DE-0699-45AA-9582-4706B9C4A3B2Q42044466-C6A79B6E-E3D5-400E-9E0D-F731FC707BEAQ42289973-7C582C3D-0A40-4EF2-B7F5-DF67AD45949CQ42371261-C5FBA2A9-0CDA-4E06-9573-5DE6A137769FQ42504823-A9D4E42E-486A-49F8-83CA-F05EE6B761F0Q45304275-5EAA6696-B0E8-49B3-A6A0-199B6790B66AQ48242863-8D5C5909-83E4-4823-A9DF-991768D661BAQ49335959-20409755-C162-45F8-826B-DB0FA9F6B377Q51737120-2803AE46-95C7-4A60-92EC-E5802AB1D205Q52430802-475AE4E7-98AD-45DD-B94E-96CAEF279CD4Q52431512-F52A324E-A835-447E-B919-E162E4517591Q55020670-192D1DEC-5087-4E69-9FDE-7AE598B49597Q55263970-AA818D4D-E9E9-4A7D-9439-1EBA63ABD7E1Q55383943-ACFA41CF-7EAC-4C3E-A859-CB71E99257BCQ55711095-D5510C0F-516E-4DCF-8DB3-6BD40A2CBB6F
P2860
Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@en
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@nl
type
label
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@en
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@nl
prefLabel
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@en
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@nl
P2093
P2860
P50
P356
P1476
Permanent inactivation of Hunt ...... d allele-specific CRISPR/Cas9.
@en
P2093
Jong-Min Lee
Jun Wan Shin
Kyung-Hee Kim
Michael J Chao
Ranjit S Atwal
P2860
P304
P356
10.1093/HMG/DDW286
P577
2016-10-01T00:00:00Z